Prédiction de la résistance à la chimiothérapie des tumeurs trophoblastiques gestationnelles (TTG) de bas risque par l’analyse de la cinétique des hCG

详细信息    查看全文

• 作者：B. You (1) (2)
  O. Colomban (1)
  M. Wilbaux (1)
  E. Hénin (1)
  M. Tod (1)
  G. Freyer (1)
  T. Hajri (2)
  J. Massardier (2)
  F. Golfier (1) (2)
  
• 关键词：Tumeurs trophoblastiques gestationnelles ; Résistance ; Aide à la décision thérapeutique ; Modélisation mathématique ; Gestational trophoblastic diseases ; Drug resistance ; Decision support techniques ; Models ; Theoretical
• 刊名：Oncologie
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：16
• 期：6
• 页码：300-305
• 全文大小：259 KB
• 参考文献：1. Chalouhi GE, Golfier F, Soignon P, et al. (2009) Methotrexate for 2,000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity. Am J Obstet Gynecol 200: 643-46
  2. Seckl MJ, Sebire NJ, Berkowitz RS (2010) Gestational trophoblastic disease. Lancet 376: 717-29 CrossRef
  3. You B, Harvey R, Henin E, et al. (2013) Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements. Br J Cancer 108: 1810-816 CrossRef
  4. Osborne RJ, Filiaci V, Schink JC, et al. (2011) Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol 29: 825-31 CrossRef
  5. van Trommel NE, Massuger LF, Schijf CP, et al. (2006) Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol 24: 52-8 CrossRef
  6. Kerkmeijer LG, Thomas CM, Harvey R, et al. (2009) External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease. Br J Cancer 100: 979-84 CrossRef
  7. Savage P, Seckl M, Short D, et al. (2008) Practical issues in the management of low-risk gestational trophoblast tumors. J Reprod Med 53: 774-80
  8. Growdon WB, Wolfberg AJ, Goldstein DP, et al. (2009) Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol 112: 353-57 CrossRef
  9. Almufti R, Wilbaux M, Oza A, et al. (2014) A critical review of the analytical approaches for tumor marker kinetics during treatment. Ann Oncol 25(1): 41-6 CrossRef
  10. You B, Fronton L, Boyle H, et al. (2010) Predictive value of modelled AUC (AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with non-seminomatous germ cell tumor. Urology 76: 423-.e2 CrossRef
  11. Maillet D, Ruffion A, Perrin P, et al. Independent confirmation of the strong early predictive value of modelled PSA kinetics in prostate cancer patients treated by radical prostatectomy: results of the prospective PSAMODEL study. Proceedings of 2012 European Society of Medical Oncology Congress. Abs. 907
  12. You B, Girard P, Paparel P, et al. (2009) Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy. Prostate 69: 1325-333 CrossRef
  13. You B, Perrin P, Freyer G, et al. (2008) Advantages of prostatespecific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy. Clin Biochem 41: 785-95 CrossRef
  14. Wilbaux M, Henin E, Colomban O, et al. (2013) Benefit in progression-free survival (PFS) to expect based on CA125 reduction at week 6 in recurrent ovarian cancer (ROC) patients: CALYPSO phase III trial data (a GINECO-GCIG study). Proceedings of 2013 American Society of Clinical Oncology Annual Meeting. Abs. 5547
  15. Wilbaux M, You B, Oza A, et al. (2014) Prediction of longitudinal tumor size changes induced by chemotherapy using modeling of CA-125 kinetics in recurrent ovarian cancer patients. Br J Cancer 110(6):1517-524 CrossRef
  16. You B, Colomban O, Heywood M, et al. (2013) The strong prognostic value of KELIM, a model-based parameter from CA125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECOGCIG study). Gynecol Oncol 130: 289-94 CrossRef
  17. You B, Pollet-Villard M, Fronton L, et al. (2010) Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol 21: 1643-650 CrossRef
  18. You B, Deng W, Henin E, et al. Validation of the predictive value of modeled hCG residual production “hCGres-in low-risk gestational trophoblastic neoplasia (GTN) patients treated in GOG-174 phase III trial. Proceedings 2012 ASCO Annual Meeting. Abs. 5110
  19. You B, Colomban O, Harvey R, et al. (2013) Comparative analysis of hCG kinetic profiles in a large International cohort of patients with low-risk gestational trophoblastic neoplasia (GTN) treated with different treatment regimens. Proc. ISSTD 2013
  
• 作者单位：B. You (1) (2)
  O. Colomban (1)
  M. Wilbaux (1)
  E. Hénin (1)
  M. Tod (1)
  G. Freyer (1)
  T. Hajri (2)
  J. Massardier (2)
  F. Golfier (1) (2)
  
  1. EMR UBCL/HCL 3738, université Claude-Bernard-Lyon-I, hospices civils de Lyon, F-69310, Lyon, France
  2. Centre de référence des maladies trophoblastiques, hospices civils de Lyon, F-69310, Lyon, France
  
• ISSN：1765-2839

文摘

Early determination of the resistance risk to firstline chemotherapy in patients with low-risk gestational trophoblastic disease would be helpful. The strategies based on one hCG time point measured during the 1st or the 7th week of treatment are not reproducible enough. Model-based approaches that enable calculation of the mathematical equations of hCG individual kinetics are promising. The reproducibility of the early predictive value of modelled kinetic parameters was shown in three large international studies. It should be possible to define for any patient her risk of resistance by integrating the hCG values measured during the first 50 treatment days in a program. An international validation of this concept is planned.